<DOC>
	<DOCNO>NCT02320357</DOCNO>
	<brief_summary>CD40 Ligand ( CD40L ) identify key feature systemic lupus erythematosus ( SLE ) pathogenesis , systemic autoimmune disease characterize multiorgan involvement . As platelet major source soluble CD40L ( sCD40L ) , propose study effect clopidogrel , platelet inhibitor , plasmatic sCD40L level SLE patient .</brief_summary>
	<brief_title>Pilot Study Related Effect Clopidogrel Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous</brief_title>
	<detailed_description>Type I interferon ( IFN ) CD40L identify important SLE pathogenesis ( 1 ) . CD40L consider biomarker lupus activity ( 4 ) . Because platelet represent major reservoir CD40L , previously study role platelet derive CD40L SLE pathogenesis ( 5 ) . We show platelet SLE patient activate vivo circulate immune complex compose autoantibody bound self antigens Fc-gamma Receptor IIa ( CD32 ) -dependent mechanism . Further , platelet activation correlate severity disease activate platelet form aggregate antigen-presenting cell include monocyte plasmacytoid dendritic cell . In addition , activate platelet enhance IFN-Î± secretion immune complexes-stimulated plasmacytoid dendritic cell vitro CD154-CD40 interaction . In lupus prone mouse , depletion platelet administration clopidogrel improve measure disease activity overall survival . In pilot study treatment research clopidogrel give dose 75mg day . For feature treatment , contraindication , disruption case side effect cf annex 1 . Clopidogrel associate usual treatment patient give 12 week , follow patient 16 week , side effect occur period record .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Diagnosis SLE accord revise criterion American College Rheumatology Being affiliate health insurance Having sign inform consent ( late day inclusion examination require research ) &gt; 20mg/day prednisone equivalent &gt; 7 day 30 day preinclusion . Diseases flare 3 month inclusion . A disease flare define increase SLEDAI score &gt; 3 change immunosuppressive treatment increase steroid dose . Is treat received 3 month preinclusion steroid pulse intravenous immunoglobulin . Renal involvement could require kidney biopsy . Required surgery next 12 week . Has treat cyclophosphamide 3 month preinclusion . Has treat biotherapy 6 month preinclusion . Contraindication clopidogrel ( annex 1 ) . History cancer except heal basal cell carcinoma . History severe hemorrhage Disease expose hemorrhage Associated antiphospholipid syndrome Pregnant breastfeed woman No contraception woman childbearing age Severe hypertension Ongoing statin , nonsteroidal antiinflammatory , antiplatelet anticoagulant drug . Being guardianship Patient participate biomedical research exclusion period screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Platelet activation</keyword>
	<keyword>CD40 ligand</keyword>
	<keyword>CD154</keyword>
	<keyword>Interferon alpha</keyword>
	<keyword>clopidogrel</keyword>
</DOC>